Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thiotepa + Fludarabine + G-CSF + Cytarabine + Busulfan for UCBT in Elderly Hematologic Malignancies
NCT07441967Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
01
Overview
A Phase 2 trial of thiotepa, fludarabine, granulocyte colony-stimulating factor, cytarabine, busulfan in hematologic malignancy, sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
thiotepafludarabinegranulocyte colony-stimulating factorcytarabinebusulfan
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT07441967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441967.